The American Heart Association/American Stroke Association have updated guidelines on secondary stroke prevention, with a recommendation for PFO closure in selected patients. MAT-2107557 v1.0| Item approved for Global OUS use only.


Amplatzer™ PFO Occluder

The Leading PFO Closure Device1

For patients who have had a cryptogenic stroke and have a patent foramen ovale (PFO), clinical trials have shown that they can benefit from PFO closure.2-4

The Amplatzer™ PFO Occluder significantly lowers the risk of recurrent ischemic stroke and offers an excellent safety profile.1

PFO Trials Represent a Turning Point

Three large clinical trials have confirmed the superiority of PFO closure to medical management in reducing risk of stroke recurrence.2-4

One study, the RESPECT trial,2 is notable for several reasons:

  • Excellent safety and efficacy outcomes from the largest PFO trial to date
  • More patients enrolled and evaluated 
  • The most extensive patient follow-up: 5,810 patient years of data

First on the Market, Still First Worldwide

The Amplatzer PFO Occluder set the standard, pioneering treatment with a device developed specifically for PFO closure. Such leadership is one reason physicians can rely on the Amplatzer PFO occluder, since:

  • As an industry-leading design, it facilitates easy closure
  • Over 130,000 devices have been implanted worldwide1



Implant Animation

PFO closure with the Amplatzer PFO Occluder is demonstrated in this brief video.

MAT-2010605 v2.0 | Item approved for Global OUS use only.

  1. Data on file at Abbott.
  2. Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017;377:1022-1032. doi: 10.1056/NEJMoa1610057.
  3. Søndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017;377:1033-1042. doi: 10.1056/NEJMoa1707404.
  4. Mas J-L, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017;377:1011-1021 and supplementary appendix. doi: 10.1056/NEJMoa1705915.

Sign up

Receive updates from Abbott Structural Heart


Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.


You are now leaving Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.